Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From around the bend...
www.mbtmag.com/video/video/22172031/worlds-first-marijuana-breathalyzer-nearly-ready
Any predictions about Cannabix's response to HL?
I'll take a wild guess and predict no less than a few news releases by year end - all stating the same thing about testing or tweaking some thingamajig on the 4.0 prototype.
Carthnel, have you ever seen any device at Cannabix in action in all of 8 years?
Somehow this year will miraculously be different?
It's my firm belief Cannabix is AT MINIMUM 5 Years away from getting beyond a prototype phase.
If ever!
Thus, Cannabix is now targeting Germany as a potential market with the clear understanding HL is about to run the North American table for a real world marijuana breathalyzer.
Tic Tok
M$
Regarding Ninnion's Ischemic Stroke clinical trial timeline:
55
Yeah, you got something alright. Something more like receiving a bend over versus "news" from around the bend. Yeah, someones occupational title determines who is or isn't a hero in the eyes of others. While we're on the subject of occupations that person you diminish is also a Director and Producer. Meanwhile, here's another example of everyday heroes:
My guess is you're not paying attention eh? That lame brain news release is a retread of a bazillion previous "news" releases by Cannabix. Simply replace 4.0 with 3.0 or 2.0 or "Beta" this and Beta that. Yeah, another road show in the deep south does absolutely nothing but keep the story going until the bottom finally falls out. Meanwhile, enjoy your merry go round.
Why I bother...smh.
M$
Well...Well...Well. What Do We Have Here?
We have a "pure comparison" to Algernon's DMT angle for Ischemic Stroke.
Ninnion is a start up psychedelics biotech company established as recent as November 2020.
A read of their news release and website narrative for Ischemic Stroke is damn near the same script as Algernon.
https://newsdirect.com/news/psychedelic-pharmaceutical-startup-ninnion-announces-patent-filings-and-development-of-nin-s119-for-ischemic-stroke-796315381
As of now Ninnion plans a Phase 1 Ischemic Stroke clinical trial in Q1 2023. It will be a sure fire comparison to how they execute their timelines to data readouts at each stage.
Anyone willing to place a bet Ninnion will likely run circles around Algernon's timelines just as Bellus Health dors with Chronic Cough?
My guess is Ninnion will run clinical trials in good ole USA versus searching for cover high and low in any country other than North America.
Surely, there will be those laying claim and calling foul because Ninnion appears to be a private company. So what, it doesn't change the timeline comparison one iota.
Shout out to PretEnders @ stocktwits for the Due Diligence scoop.
Ninnion website: https://ninnion.com/aboutus/
There's a saying about it not being about how you start, but rather how you finish. In Algernon's case history, Algernon starts weak and finishes even weaker.
Happy Tuesday (Q2 2022),
M$
Happy Sunday!!!
M$
2 COVID studies (SK & Romania) not powered for stat sig = Bogus
IPF/CC study not powered for stat sig = Bogus
Running clinical trials on the ultra cheap in Australia = Bogus
Claiming to bypass Phase 1 studies to go straight to Phase 2 = Bogus
Everybody wants in at Phase 2 = Bogus
65% chance of successful data readouts due to no safety concerns = Bogus
Equating the BS that comes out of Moron Moreau's pie hole on a regular basis to a Playing Card Dealer = Bizarre Bogus
There is a litany of shit Moeau has told shareholders that simply never held water.
One thing he didn't tell shareholders was he conducted private updates to BioPub subscribers.
Anyone have a clue why BioPub appears to no longer be on the Pennyland webcast list?
It probably has something to do with shareholders finally catching onto their conflict of interest collaboration.
Anybody here ever willing to stand up against that type of Bogus representation coming from management?
Crickets...
I thought so.
Do you and thank your lucky stars I'm gonna continue doing me.
M$
Who DEPENDS on others Due Diligence for understanding?
Who wears DEPENDS adult diapers?
Who enjoys apologizing and appeasing getting crapped on by Beer Buddy?
Nobody can stop insiders ilk/entourage from posting here.
Yeah, that's who!
Have fun,
M$
You have answers in black and white directly from the company. It's your interpretation of what's written that remains waaay off the mark. Also, this msg board has never had a large number of regular participants. Breathtec/Algernon has never captured the interest of the masses like a pot stock and now even a Psychedelic stock. That's a management problem not a msg board participation problem. If they had a "Winning Strategy" (a King Cobra quote) this msg board would likely be lit up like Christmas. Instead, you can always expect a lump of coal stuffed in your stock-ing @ Algernon Pharmaceuticals Inc. Management has driven the bus over the cliff and shareholders remain under the wreckage. Don't expect anyone to get too excited about Phase 1 clinical trials in 2023 and 2024 - because "Everybody Wants In At Phase 2" in 2026 or 2027 for data readouts.
M$
You continue to ask many of the same questions that have clear answers.
Have @ it
M$
Postscript
When I'm done posting here - I'm considering starting a blog with others for all things biotech - with a particular focus remaining on Algernon's haphazard journey.
@algernonpharma.com
Someone please tell Beer Buddy I said hello.
You think Algernon actually has competition? Yeah, we see how Algernon stacks up against companies that are winners like Bellus Health ($850M market cap/Chronic Cough) or GH Research ($1B market cap/one trick pony/ DMT). Those are real companies getting real value for shareholders. The type of "competition" Algernon wants to model is Xortx ($25M market cap/Chronic Kidney Disease). Xortx is a recently uplisted penny stock (sub $2 per share) trading on Nasdaq. Christopher Moreau recently hired their former CEO to "advise" on business strategy - smh.
Algernon is not competing with ANY company chasing after Cancer or any other disease given Algernon's foot dragging timelines to data readouts. I would have thought you were aware that there's more than one type of Cancer. Cancer competition? Also, you seem to want to understand a capital raise is coming with an uplist or not. My point has always remained the same here. I just keep explaining it to you over and over again. A capital raise is coming BEFORE any of the clinical trials are completed. They need money now - period.
(I'll reserve this space to say it all again a billion more times)
M$
What form of Cancer? Please name the company. Also, still haven't wrapped the mind around the fact the F-1 filing is the immediate avenue to a capital raise eh? Kinda crazy to think no uplist or capital raise will take place until after those Phase 1s are completed. It just shows no matter the efforts to explain the obvious it takes getting smacked between the eyes to clearly get the picture.
M$
You do know it's an end of life story right? Kinda like compassionate use. It's not curing or eliminating anything but the patients worries. Whereas DMT for stroke is going after a treatment. Two completely different levels of hurdles to climb. However, surely the shrooms companies of the world, you know those with flying high all the time shareholders, will use it as some prop to pump their flailing stock.
Meanwhile, I'll take this opportunity to revise my own interpretive timeline for Algernon's pipeline. I continue to believe there will not be any clinical trials launched in 2022 other than DMT. The Cancer angles will be stalked just like DMT one quarter after the next (one more stalk and it will be a calendar year passing below your feet) until 2023. The Cancer angles will probably start sometime in 2023.
However, the start of the next Phase 2 study is thus far claimed to be DMT. I wouldn't expect Algernon to get to a data readout for DMT until Q4 2025 at best, but more likely in 2026. 2026 will be your 1st data readout powered for stat sig (maybe - gotta see it first) in the company's history. Moreau will have been at the helm going on 8 Years before he gets one real clinical trial completed at Phase 2 ("Everybody Wants In At Phase 2" - Moreau). It's the most pathetic timelines that are rife for minimum momentum and massive dilution.
Have @ it
M$
Sure thing buddy. Let me know when ur in position to rebut the trash technology at Cannabix. All I'm gathering is a chip on the old shoulder. Otherwise...til next time.
Yeah, in the real world DW is a hero in many eyes.
M$
Algernon Pharmaceuticals push back start of DMT Phase 1. First scheduled to start in Q4 2021 then Q1 2022 then Q2 2022. The latest SEC F-1 Filing now states DMT Phase 1 to start Q3 2022. Anyone have any guess on where DNT is headed next?
Yeah, all those Phase 1's look good on paper eh?
What I see is 3 multiple avenues of disappointment in 2022 just in time for the holidays as usual.
Of note: Uddin's market valuation ($33M) of Algernon Pharmaceuticals places ZERO value on any of the Phase 1 studies in the pipeline.
Uddin's entire valuation (paltry at best/sinister at worst) is based on the pending IPF/Chronic Cough data readout.
Andre Uddin is ranked in the Top 5 Percent among his Walk Street peers per "Toprank".
Crazy Ch!t A!nt !t
M$
"It's not what you know, it's what you can prove." - Denzel Washington, Training Day
Prove I'm here making shit up about Cannabix.
M$
I have not seen the 45 minute window you suggest regarding a window of detection. What I will say is a 45 minute window makes a THC device practically useless. You're talking about trying to catch someone who has basically smoked right next to you before going about their business. Such a radical timeline is just that - Radical. And, it would further prove Cannabix's technology is inferior and headed for a junk pile in due time. Whether the Cannabix story continues to capture those who remain clueless about what's really happening at Camp Cannabix - they'll ultimately find out it's all one big charade.
Point being, there are no scientists that believe impairment does not stretch far beyond 45 minutes of consumption. So, detecting THC (not impairment) within 45 minutes of use eliminated the vast majority of those who would be under the influence (DUID) far beyond 45 minutes. People need to simply think matters through in a practice way. A 45 minute window if detection is impractical and useless.
Of note: The science also states thc in edibles are detected in breath at a completely different rate (timeline) than smoking. If anyone actually saw the disastrous Texas Forum presentation by Dr. Boock - you would know he ducked a direct question regarding detection of THC from edibles. What's their actual timeline that begins to detect THC front edibles? Edibles could take hours to reach the breath (lungs). Impairment can last considerably longer from edibles than smoking. Many hours longer. As I've said it's all a charade and the so-called data coming from Cannabix will continue to change with the wind.
M$
Correction to last post added here:
Nobody cares about the approval of a Phase 1 study for DMT. So look to next year for any outside interest. Also, your 50M market cap number is one that no one has come up with yet.
Go back to Uddins 20 cent per share price target. That was based on 167M shares outstanding. That gets Uddins analysis to roughly $33M USD market cap.
Uddin places zero value on DMT or Cancer at Phase 1. Now take Uddins analysis and add 2.5x dilution to the equation. That's where this thing is headed!
To make it simple to comprehend (hopefully) is to take the original 167M shares and times it by 2.5 (2.5). That's the pre 100 to 1 reverse split calculation. Where now it's 1.67M shares times 2.5 (2.5).
Therefore, a $33M USD market cap (per Uddins analysis) with 4.175M shares outstanding is $7.90 per share price - effectively 7 cents pre reverse split.
Understanding the math provides you with a clearer picture - period. Management doesn't expect you to understand the math and the devastation the 100 to 1 reverse split has caused to shareholders.
Algernon will most likely fire sell shares around the $4 USD per share to get to it's $9M USD capital raise. Add another million shares for the cost of doing business. Hence, a $10M USD fire sale.
I come to these numbers using Uddins own numbers (Uddin is Algernon's go to guy) and the numbers represented in the F-1 filing to uplist to Nasdaq. I'm not flying off the handle here with wild and outlandish opinions.
If none of this "makes any cent's" to anyone - no worries. It will smack you right between the eyes soon enough. The Massive Dilution Train is a coming to your account soon.
Hard to believe I still do dis sh!t fo free.
Only In America!
M$
I'll continue beating a Dead Horse because Algernon's CEO refuses to learn lessons. Moron Moreau is still peddling his "Everybody Wants In At Phase 2" BS elevator sales pitch.
Try this exercise when you get a minute - go to XORTX website. Pull up their pipeline. See where they list two Phase 2 clinical trials in progress or completed.
Now go to clinical trials.gov and see if you can find anything with Cortex name on it.
What I see coming from Xortx is a bunch of mumbo jumbo BS studies that aren't designed to go anywhere beyond Phase 2 studies.
It's the same shit show penny stock antics Algernon had pulled off since inception (2018) of it's "Repurposed Drugs Strategy".
Cortex is a hot mess. Moron Moreau had embraced Xortx as another pure comparison to Algernon Pharma.
Now go look at Cortex 1 year chart since their uplist to Nasdaq. See their 52 week Hi,
/Low. That shit ain't getting any better anytime soon if ever.
Xortx should be an example of what not to do regarding performance,/shareholder value. Their shareholders have been raked over the coals since massive dilution and uplist.
Moron Moreau is forecasting exactly what is on the immediate horizon for Algernon based on his retread of the same lame ass communication angles that do not work.
My best guess is the latest infomercial is targeted to some low level institutions and their usual suspect list of private placement participants.
Yeah, another bonfire fire sale of millions of shares will get them a quick flip after their brief 4 month lockup period.
Moreau always makes like 4 months is 4 years when it comes to the Cayman Island Crew offloading their fire sale shares at the 1st sign of stock movement.
Beyond all of Moron Moreau's continuing one track mind sessions to the masses, their go to Analyst ( Andre Uddin) continues to paint a bleak picture for current reverse split shareholders.
Uddin believes there's hope with data coming from the IPF/Chronic Cough study still ongoing in Australia. I believe Uddins analysis will be dead wrong just like his previous analysis he walked back.
Xortx stock dropped below $1 USD pist Nasdaq uplist. I'm of the belief Algernon will see $2 again post sn uplist - if an uplist ever happens.
Without the uplist Algernon stock will drop below $1 with the massive dilution headed it's way on a bullet train.
As I've stated in previous posts, I do not see Algernon coming anywhere close to Phase 2 data (not including the long awaited IPF/Chronic Cough data) before calendar year 2025.
Algernon has reversed itself to now being a Phase 1 company. It has not lived up to what they sold the public with it's BS chart showing entry at Phase 2 enroute to Phase 3.
Its been all BS. Hence, the need for Moron Moreau to now claim the company is going to concentrate on "fundamentals".
I guess that's suppose to mean they decided all the FUN and games they play along with King Cobra may finally bite them in the ass due to lack of credibility to say the least.
Keep a $30 USD share price in mind as a break even target post the 100 to 1 reverse split.
Anyone still holding shares from the 2 to 1 reverse split before the 100 to 1 reverse split is looking at $60 USD share price to break even.
Moron Moreau had done long term damage just like he did at Miraculins for 10 years. One failed story after another. Year after year after year after year.
In the entirety of calendar year 2022 - the only clinical trial that will take place is the Phase 1 DMT study. That's it. Period.
So what's the point of Moreau peddling Phase 2 dreams at this juncture? He's got nothing else to peddle to the public knowing massive dilution is coming in 2022.
Now go back to Cortex and just look at all their "stuff". Another swing for the fence, wild and outlandish attempt at COVID-19 - failure. Clinical studies not designed to go anywhere but back to the drawing board - (the Algernon way). Massive dilution and uplist to Nasdaq. A friggin $1 stock.
Yeah. Moreau loves all of that type of action. That's why Xortx's recently resigned CEO is now whispering words in Moreau's ear as Algernon's new/latest/only Business Advisor.
Shareholders are cursed and laughed at by the Devil (King Cobra & Crew).
Cell Phone on the Highway - F Spell check,
M$
FYI: If you believe knowing what the #1 competition is up to is relevant to your investment decisions which is usually the norm in the real world (business 101)...
Hound Labs, Inc.
@HoundLabsInc
Meet us at the
@NSCSafety
#WorktoZero Summit and Expo on April 13-24. We’ll have the HOUND® MARIJUANA BREATHALYZER for demos at Booth 105. https://nsc.org/workplace/safety-topics/work-to-zero/summit #NSC #workplacesafety
12:26 PM · Apr 4, 2022
___________________
The last time Cannabix participated in an event with a version of its many prototypes to date was back in May 2015.
www.buzzfeednews.com/article/amandachicagolewis/everyone-wants-a-marijuana-breathalyzer-but-no-one-knows-if
How pathetic is that?
M$
Assessing cough symptom severity in refractory or unexplained chronic cough: findings from patient focus groups and an international expert panel
Published By:
European Respiratory Society
Online ISSN:
2312-0541
History:
Received November 26, 2021
Accepted January 14, 2022
Published online March 14, 2022.
https://openres.ersjournals.com/content/8/1/00667-2021
Introduction
Share Price is all fluff. 60 shares traded on the CSE today @ $6 CAD. Algorithm trading on OTC aligned the two. Welcome to the Matrix of Manipulation.
Live to Learn another day.
M$
A follow up for GOLD DIGGER:
www.huffpost.com/entry/marijuana-decriminalization-house-passed_n_6246f124e4b068157f765162
Yeah, wouldn't be surprised if Moron Moreau used that COVID/fibrosis angle to somehow justify not running a standalone Chronic Cough study but rather the same disastrous coupling of IPF & Chronic Cough to stretch out a data readout to oblivion. Meanwhile, patting each other on the back and doling out more shares to themselves.
Remember: Bellus Health ran their Phase 2 Chronic Cough study in the USA for hundreds of participants from enrollment to a final data readout in less than 1 year.
Just watch how many years you'll wait for a readout coming from Australia if ever.
Oh, that's right. Everyone is still waiting for the 1st insignificant 20 patient data readout since July 2020 coming from Australia by way of Kangaroo.
M$
I get it. Islanders are still sleepwalking by the time the stock markets close.
Booyah,
M$
YO GOLD DIGGA
I'M NOT NEW TO USA POLITICS.
TRUST WHEN YOU READ THIS QUOTE THERE WILL BE NO LAWS PASSED IN YOUR LIFETIME THAT WILL BE RESPONSIBLE FOR PROPELLING CANNABIX INTO THE STRATOSPHERE - IT REQUIRES AN ACTUAL PEER-REVIEWED AND SCIENTIFICALLY ACCEPTED WORKING DEVICE.
PERIOD
www.forbes.com/advisor/personal-finance/house-vote-marijuana-legalization/
Definitely a sign of desperation the day before April Fools Day. How fitting.
ROTFLMAO
One obvious point is legalization of marijuana in the USA has already taken place at the state level. There is no laws being passed in the USA that will impact Cannabix's ability to come forward with a working device. It's about the device not a dumb-ass law. If it were about laws then Cannabix would have capitalized on the marijuana laws passed in it's own backyard in Canada in 2017. 5 Years ago! Just more BS look over there distractions from the fact Cannabix has crappy technology - Hound Labs has peer-reviewed technology - and Cannabix will be shut out of the USA market if it ever gets its act together which remains highly doubtful. Did anyone here ever see that Texas Forum presentation by Dr. Boock? Obviously not! It was a pure disaster.
Once again, you are being fooled into thinking some law is going to save Cannabix. Like the BS narrative Cannabix put forth about legalization of marijuana in Germany four or five years from now. Just more crazy stupid foolish stories to throw at the masses of potheads with their head in the clouds.
M$
To All In @ Algernon Pharmaceuticals Inc.
Happy...
April 1, 2016 - AGNPF - 63.30 High
April 3, 2017 - AGNPF - 23.42 High
April 2, 2018 - AGNPF - 34.38 High
April 1, 2019 - AGNPF - 20.70 High
April 1, 2020 - AGNPF - 17.11 High
April 1, 2021 - AGNPF - 20.00 High
April 1, 2022 - AGNPF - 4.84 is the High as of yesterday.
There is plenty of Darkness in the numbers above.
Just facts.
M$
The best thing that could ever happen for anyone with money stuck at Algernon Pharmaceuticals is to fire the entire group of people employed at the "Virtual Reality" company. Fire everyone with the exception of Dr. Mark Williams and Dr. Marilyn Huestis. They're the only ones who bring any valuable expertise to the table. Huestis should be appointed to the Board of Directors with Williams as Chairman. Bring in a real CEO with a winning track record. There's a bunch of losers at Algernon Pharmaceuticals. Their stripes will never change but keep hope alive.
M$
I've Got 6 Years & 6 Figures Down The Bloody Drain @ BTHCF/AGNPF
Meanwhile, Algernon Pharmaceuticals sits on the cliff__precipice of bankruptcy with approximately 1M USD in cash on hand. Now awaiting a financing approval of 10M USD to move forward with the following studies:
From the most recent F1 Filing Dated March 22, 2022:
Description of Use Estimated Amount of Net Proceeds
General and Administrative Expenses (12 months) US$[1,300,000]
IPF/Chronic Cough - Ifenprodil
Phase 2 (Australia) US$[500,000]
Stroke - DMT
Phase 1 US$[2,000,000]
Phase 2 Acute US$[3,000,000]
CKD - Repirinast
Preclinical US$[800,000]
Phase 1 US$[800,000]
Unallocated Working Capital US$[600,000]
Total US$[9,000,000]
We would receive additional gross proceeds of approximately US$[?] if all of the Warrants included in the Units are exercised, assuming no exercise of the underwriters' over-allotment option. We intend to use any such proceeds for working capital and general corporate purposes. General corporate purposes may include capital expenditures. Amounts listed are the total estimated to complete the listed phase. The Company has approximately CAD$1,600,000 in cash on hand as of March 21, 2022 in order to further fund operations and complete the programs noted in the use of proceeds table.
ir.algernonpharmaceuticals.com/sec-filings/all-sec-filings##document-44-0001062993-22-008449-2
Let's go down the list of the above planned activities.
Does anyone remember the recent Q&A with Christopher Moreau where the question was asked about running a standalone Chronic Cough study in the USA versus Australia/New Zealand? If not, Moreau gave a mealy mouthed answer by stating leadership was weighing the options to run a USA trial for expedience versus AU/NZ for cost savings. Moreau is acutely aware of the slow process in AU/NZ for clinical trials. Yet, what is actually on paper for would be Nasdaq investors...in black and white Algernon is asking and allocating money for not a standalone Chronic Cough study, but Algernon is actually going to run another IPF study with Chronic Cough attached. Moreau already told the market you don't run Chronic Cough studies with IPF patients because the IPF patients are usually very sick people. Hence, making the task to get to statistical significance that much more challenging. It would seem leadership is 100% content with slowly rolling the results of any Phase 2 study coming out of the pipeline. Moreau continues to toss out Bellus Health's name as a pure comparison but refuses to follow in their footsteps to get to data readouts. Bellus Health gave themselves multiple shots at goal with multiple arms/doses/primary endpoints. Bellus Health will likely succeed at Phase 3. Which is why I've taken a position in their stock. Someone please muzzle Moreau about Bellus Health. He is not in their league on any level. What also needs to be noted about the IPF/Chronic Cough study is there is no timeline for which it will start. There is absolutely nothing on the pipeline illustration that states an IPF/Chronic Cough study will start anytime in the future. I suspect it will roll out sometime in the latter part of 2023. Maybe Q4 if you are lucky. However, the IPF/Chronic Cough do-over will likely not report final data until maybe 2025 or 2026. You have the past as your timeline guide here. What else are you going to go on - Christopher Moreau's mealy mouthed word?
Moving onto DMT. We already know the company has pushed back the timeline start of a Phase 1 study by 6 months already. From Q4 2021 to Q1 2022 (6 months) and now it's Q2 2022 with no real handle on when that tiny study will finally start. Their goal now is to start a Phase 2 DMT study in Q1 2023. It';s reasonable to assume Algernon will miss at least one quarter of its stated goals. Thus, expect a Phase 2 DMT study to begin sometime in Q2 2023. The question remains (I think) of how long will such a study take to get to a Data Readout? My best guess is 2 years (Q2 2025) given Algernon's inherent slow roll of studies. Surely it will be a study conducted in a foreign country. Anywhere other than North America seems to be part of their game plan which minimizes direct accountability. Moron Moreau has recently called Algernon Pharmaceuticals a "Virtual Company". What I do know for sure is the 6 figures I've lost are not virtually/nearly/almost missing from my account balance. Right along with my share count evaporating before my eyes. Half of all the proceeds are going to DMT and the best you will get is a half ass timeline to data that will not be completed before the next capital raise beyond the pending capital raise.
As far as the CKD study goes...who knows? Who knows when that study will actually start because it remains based on Moreau's mealy mouthed answer to when the drug (Repirinast) will be made available for the study. However, we can see from the pipeline chart below there is no Phase 2 study on the horizon. Thus, it's another slow roll of a Phase 2 data readout IF successful at Phase 1. To date, CKD seems iffy and not planned to be done in a jiffy. Thus, I'll stick it in the data readout time frame of 2025 along with DMT.
Does anyone remember the phrase stated on multiple occasions that "EVERYBODY WANTS IN AT PHASE 2" - Christopher Moreau
Well, if that were ever true of a clinical stage company then you wouldn't expect to place any bets on Algernon Pharmaceuticals until sometime in the Phase 2 process. That means not likely until 2024 given their slowly rolling timelines. Thus, I have placed bets in other companies in the Phase 2 and Phase 3 part of the process. One psychedelic company has 2 Phase 2 data readouts coming in 2023. That's close enough to gamble on a multi-bagger and potential buyout in the stratosphere for a 1st to market mover in the psychedelic sector. Plus, they have world class management/BOD/Advisors from around the globe in all areas of pharmaceuticals and financing. true world class clinical stage companies. I thank Algernon's leadership for clearly pointing out the difference in the caliber of characters one should look for when investing. Algernon's team is a glaring example of the worst type of people to bet on. IMO, significantly flawed characters remain at Algernon Pharmaceuticals Inc.
In the final analysis I'm very close to closing out my entire position here. I'm sure you all will be thrilled. Moving forward into 2023 (12 months from now) you can expect yet another capital raise. In that event you can expect Moreau to go after at least 20M USD to move any new found drugs to re-purpose based on Dr. Mark Williams candlelight reading of books. At this juncture, I expect the next raise will be around the $8 USD range if you are lucky. That means the total outstanding shares will be a minimum of 10 Million shares given the exercise of warrants. Hence, Algernon could be valued at $80M USD with 10M outstanding shares valued at $8 per share. You will remain underwater unless and until a Phase 2 data readout proves to be statistically significant to warrant a Phase 3 study that likely will not start until maybe 2025 or 2026 with a data readout some years beyond that. As Moreau the Moron stated Algernon has a long way to go to realize whatever value their leadership places on the company overall. My best guess is they could care less. They are making money hand over fist (The 1%) no matter what happens on whatever timeline.
Live and Learn from the Past or Continue Dying On The Vine
M$
PostScript
Shout Out To Medchem. He sounded the alarm back at the Interim Data Readout (Dec 2020) of COVID-19 that it was all a scam and time to bail. He was 100% right. Good for Medchem to cut his losses if any.
Outro
Redux to my previous post.
Prior version was done on mobile phone.
This version was done on Laptop. Enjoy.
The Appeaser strikes again with serious gaps in the truth. The COVID angle was destined for failure from the outset. As Christopher Moreau himself began walking back the expectations of Ifenprodil's success BEFORE the announcement of Topline Data in March 2021.
www.biospace.com/article/releases/algernon-pharmaceuticals-announces-topline-data-from-its-phase-2b-3-covid-19-trial-of-ifenprodil/
Prior to that, shareholders were sold a bill of goods with "Positive Trending Interim Data" in December 2020.
www.globenewswire.com/news-release/2020/12/15/2145345/0/en/Algernon-Pharmaceuticals-Announces-Positive-Trending-Interim-Data-for-its-Phase-2b-3-Ifenprodil-COVID-Study.html
Andre Uddin jumped all over the "Positive Trending Data" and dropped his rating from 80 cent to 25 cent CAD (20 cent USD). MERRY CHRISTMAS!!!The stock price never recovered above 25 cents thereafter. Thereafter, Christopher Moreau gave a full throated walk back of the COVID study by stating in so many words it would take a MIRACLE of overwhelming data to move Ifenprodil beyond a Phase 2 study. At that moment Christopher Moreau actually told the truth. He did so knowing the company had absolutely nothing to fall back on in the near future because IPF/CC remained bogged down/hog tied in Australia amidst a 2nd COVID-19 lockdown.
"Algernon to drop Phase III trial of Ifenprodil for Covid-19"
www.pharmaceutical-technology.com/news/algernon-phase-iii-ifenprodil-trial/
At the time the IPF/CC data readout was highly important data that might have kept the share price/selloff from hitting yet another historic low under Christopher Moreau's leadership. The chart clearly provides the failures without any of us attempting to explain the why. I however believe I have it correct. As I've been the primary person here explaining the blow for blow destruction of shareholder value since Christopher Moreau's appointment to Algernon. The wildly unfortunate thing is we all went along for the ride unknowing that the Repurposed Drugs plan is actually a year's long process to get anywhere close to running real statistically significant clinical trials. That's the business model they have set up to drag studies out to decide if they truly want to run real clinical trials. There's a multi-year delay to ever get to Phase 2 as the DMT and Cancer studies will also prove to be a timeline challenge. Leadership has already walked back the start of a tiny Phase 1 study for DMT and you can surely bet the Cancer angles will not start on time in 4th Quarter 2022. The start of DMT for stroke is the only actual new news (if you want to consider it news by now) that will happen in 2022 short of an uplist to Nasdaq IF that happens. Surely, no one here believed last year we'd be looking at 2nd Quarter 2022 and still no start of DMT study originally projected to start in 4th Quarter 2021 - then 1st Quarter 2022 - now underhandedly written in the corporate summary to start in 2nd Quarter 2022. How anyone can put their faith and finances with a leadership team of utterly incoherent messaging is risking it all for sure. The way Christopher Moreau blindsided us with the FAIMS technology should have been the overwhelming sign to bail out then. It's been nothing less than a path to over the cliff destruction of shareholder value (see charts posted today). Christopher Moreau's in-house analyst continues to punish the stock with a 20 cent USD buy rating AFTER the data readout of the much awaited (zzZzz) IPF/Chronic Cough study. Unfortunately, the IPF/CC study was only designed to determine IF the company will actually run a Phase 2 study powered for statistical significance to move to Phase 3 IF ever statistically significant/successful at Phase 2. Thinking of our “pure comparison" company - Bellus Health. Bellus Health is sitting on a pretty good 750M USD market cap with multiple analysts claiming their market Cap will double at Phase 3. It's hard to reconcile Andre Uddin believes Algernon's market cap is worth 35M USD at best AFTER the data readout of IPF/CC. Then again, he surely knows the data will not push the clinical trial process to the next level at Phase 3. Thus, one must factor in another 2.5M shares issued for a $10M USD capital raise and uplist to Nasdaq. If once the dust settles, the math suggests a 35M USD market cap with 4.1M shares outstanding. A 35M USD Market Cap @ 4.1M shares outstanding = $8.50 USD stock price. That sounds about right for the penny-ante leadership at Algernon Pharmaceuticals. Any other company worth it's words would have ran Andre Uddin and his anal-ysis out of town. Instead, Algernon’s leadership embraces Uddin’s "mathematical" logic in which they know the vast majority of shareholders will remain underwater swimming for dear life. Meanwhile, the next batch of Private Placement holders out of the Cayman Islands and living rooms of management will likely suffer no loss as they buy up shares around $4 per share. That's been adopted by leadership as "A Winning Strategy" - courtesy of Kulwant Malhi @ Cannabix Technologies Inc. Unfortunately, the "Repurposed Drugs Strategy” has not done well for Algernon shareholders as it's done for Kulwant Malhi’s personal portfolio and GrowMax Capital since renamed Coloured Ties Capital. I've called for the resignation of Christopher Moreau ever since dumping the FAIMS and I continue to do so now. I believe he's a Natural Born loser in pennyland as his 10 year leadership track record at Miraculins spells out. The worst thing about that is Christopher Moreau has now insulated himself with other previous leadership team members from Miraculins. It’s an example of doing the same shit over and over again - dilute/devalue/demolish. The only other hire from failed Miraculous is Christopher Moreau's brother - Nepotism. Expect his hiring at some point in the future of Algernon. A “Virtual Company" as newly described by Christopher J. Moreau, CEO @ Algernon Pharmaceuticals Inc.
You can't make this shit up can you?
Well, at least someone can.
I thank God it's not me in La La Land.
However, $8.50 USD per share is the target price Algernon embraces for the foreseeable future.
The $8.50 above is truly 8.5 cents pre reverse split of 100 to 1 in 2021 for Nasdaq uplist.
The 8.5 cents above is truly 4.25 cent pre reverse split of 2 to 1 in 2018 to advance the Nash Pharmaceuticals pipeline purchased by shareholders.
Thus far, only one clinical trial for the disease indications purchased from Nash Pharmaceuticals in 2018 has been launched (in 2020) out of the pipeline.
The COVID-19 angle got dropped on our heads like the surrender of FAIMS.
A leadership team with a failed FAIMS strategy or simply part of the reverse takeover deal orchestrated by Kulwant Malhi?
Does everyone know Kulwant Malhi was the only stockholder of Nash Pharmaceuticals with 10% or more ownership?
No other shareholders of Nash Pharmaceuticals held a percentage of stock that required reporting.
Well, it’s all on paper in black and white.
It’s good to know hindsight is 20/20.
Otherwise, you will always be the recipient/receptacle to shit on.
Do Do you smell it yet?
M$
The Appeaser strikes again with serious gaps in the truth. The COVID angle was destined for failure from the outset. As Christopher Moreau himself began walking back the expectations of Ifenprodil's success BEFORE the Topline data was released. Andre Muffin jumped all over the Top one daya and dropped his rating from 80 cent to 25 cent CAD (30 cent USD). The stock price never recovered above 25 cent thereafter. Thereafter. Christopher Moreau gave a full throated walk back of the COVID study by stating in so many words it would take a MIRACLE of overwhelming data to move Ifenprodil beyond a Phase 2 study. At that moment Christopher Moreau actually told the truth. He did do knowing the company had absolutely nothing to fall back on in the near future because IPF/CC remained bogged down/hog tied in Australia amidst a 2nd COVID-19 lockdown.At the time the IPF/CC data readout was highly important data that might have kept the share price/selloff from hitting yet another historic low under Christopher Moreau's leadership. The chart clearly provides the failures without any of us attempting to explain the why. I however believe I have it correct. As I've been the primary person here explaining the blow for blow destruction of shareholder value since Christopher Moreau's appointment to Algernon. The wildly unfortunate thing is we all went along for the ride unknowing that the Repurposed Drugs plan is actually a year's long process to get anywhere close to running real statistically significant clinical trials. That's the business model they have set up to drag studies out to decide if they truly want to run real clinical trials. There's a multi-year delay to ever get to Phase 2 as the DMT and Cancer studies will also prove to be a timeline challenge. Leadership has already walked back the start of a tiny Phase 1 study for DMT and you can surely bet the Cancer angles will not start on time in 4th Quarter 3022. The start of DNT for stroke is the only actual new news (if you want to consider it nee by now) that will happen in 2023 short of an uplist to Nasdaq if that happens.. surely no one here believed last year we'd be looking at 2nd Quarter 2023 and still no start of DMT study originally projected to start in 4th Quarter 2032 - then 1st Quarter 2022 - now underhandedly written in corporate summary to start in 2nd Quarter 2022. How anyone can put faith and finances with a leadership team of utterly incoherent messaging is risking it all for sure. The way Christopher Moreau blindsided us with the FAIMS technology should have been the overwhelmed sign to bail out then. It's been nothing less than a path to over the cliff destruction of shareholder value. Christopher Moreau's in-house analyst continues to punish the stock with a 25 cent buy rating AFTER the data readout of the much awaited (understatement of all times) IPF/,Chronic Cough study. So study only designed to determine if the company will actually run a Phase 3 study powered for statistical significance to move to Phase 3 if successful. Thinking of our ' pure comparison" company - Bellus Health st 750M USD market cap - it's hard to reconcile Uddin believes Algernon's market cap is worth 35M USD at best AFTER the data readout of IPF/CC. If you factor in another 2.5M shares issued for an uplist to Nasdaq the math suggests a 35M USD market cap with 4.1M shared outstanding. A 35M USD Market Cap @ 4.1M shares outstanding = $8.50 USD stock price. That sounds about right for the penny-ante leadership at Algernon Pharmaceuticals. Any other company worth it's words would have run Andre Uddin and his anal-ysis out of town. Instead, leadership embraces Uddin:s "mathematical" logic where they know the vast majority of existing shareholders will remain underwater swimming for dear life. Meanwhile the next batch of Private Placement holders out of the Cayman Islands and living rooms of management will likely suffer no loss as they buy up shares around $4 per share. That's been "A Winning Strategy" - Kulwant Malhi @ Cannabix Technologies Inc. unfortunately, the "Repurposed Drugs Strategy has not done well for Algernon shareholders as it's done for Cannabis shareholders. I've called for the resignation of Christopher Moreau since dumping the FAIMS and continue to do so now. I believe he's a Natural Born loser in pennyland as his 10 year leadership track record at Miraculins spells out. The worst thing about that is Christopher Moreau had insulated himself with other leadership members from Miraculins as his new and improved inner circle on paper. The only other hire from failed Miraculous is Christopher Moreau's brother. Expect that hiring at some point in the future of the 'Virtual Company" as newly described by Christopher J. Moreau, CEO @ Algernon Pharmaceuticals Inc.
You can't make this shit up can you?
Well, at least someone can.
I thank God it's not me in La La Land.
However, it remains all pennyland bullshit @ $8.50 USD per share.
The $8.50 above is truly 8.5 cents pre reverse split of 100 to 1 in 2021 for Nasdaq uplist.
The 8.5 cents above is truly 4.25 cent pre reverse split of 2 to 1 in 2018 to advance the pipeline purchased by shareholders.
This far, only one clinical trial for the disease indications has been launched (in 2020) out of the pipeline.
The COVID-19 angle got dropped on our heads like the surrender of FAIMS.
A leadership team with a failed FAMIS strategy.
Who knew?
M$
Bottom line
Prior to Christopher Moreau
$80+ Historic High to $35+ Historic Low
Since Christopher Moreau
$40 Historic High to $2.50 Historic Low
Charts don't lie.
Morally bankrupt/corrupt leaders do.
Unfortunately Nasdaq investors are way more sophisticated than your average CSE/OTC trader/investor.
That's the semi walked back true sentiment of Christopher Moreau.
Thus, what do you think is the likelihood Nasdaq will not take a good look at the historical maintenance sheet under Moreau's ownership of leadership @ Algernon Pharmaceuticals Inc?
Nasdaq has likely already seen the CARFAX of this wrecked and wretched biotech company.
Miracles for all is what's most likely required moving forward.
BH
Here is AGNPF chart prior to Christopher Moreau:
Chart #1
Here is AGNPF chart since the appointment of Christopher Moreau:
Chart #2
Please note the overall stock price listed on the right side of the first chart. Those numbers represent BOTH stock splits of 2 to 1 and 100 to 1.
Do you see how the historic high in the first chart (before Moreau's leadership) is double the historic high of the second chart?
The first chart represents the Breathtec Biomedical FAIMS technology that now sits solo at Cannabix Technologies Inc - a Kulwant Malhi company.
The second chart represents the Algernon Pharmaceuticals Repurposed Drugs Strategy.
Christopher Moreau, CEO @ Algernon Pharmaceuticals dumped the FAIMS technology.
What shareholders got for it in return for multiple years of investment/collaboration alongside Cannabix Technologies is Chart #2.
Chart #1 All-time High. Chart #2 All-time Low.
BH
Full Disclosure: The majority of my position in AGNPF is sold.
Given the current all-time lows and complete uncertainty with timelines and data readouts I see no true upside for at least another 2 years if ever.
Pre-split shareholders (2 to 1 and/or 100 to 1) already need a multi bag stock price to get out of the red.
Couple that to no significant Phase 2 data readouts at least until 2024.
Couple that to Andre Uddin placing a .20 Cent price target on AGNPF with DMT, Chronic Cough, Cancer knowingly in the [pipeline for advancement.
I'll continue to do a helluva lot better in profits or losses with my money practically invested anywhere but AGNPF over the next 2 plus years.
What a real shit show @ Algernon Pharmaceuticals Inc.
BH
Anyone believe this is a good thing for Cannabix?
https://www.syracuse.com/marijuana/2022/03/in-wake-of-marijuana-legalization-ny-police-focus-on-impaired-driving.html